SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2021 Biotech Stock Picking Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: FiloF who wrote (128)4/9/2021 2:29:31 PM
From: Bladerunner17  Read Replies (1) | Respond to of 307
 
FILO,

I have PRVB in my Contest portfolio. Enough said.

The only good news for me was that I sold my entire position in the 12's in my real portfolio. Still took a loss.

Bladerunner

P.S. CRDF has been another big loser for me in the Contest.



To: FiloF who wrote (128)4/9/2021 4:45:37 PM
From: BulbaMan  Respond to of 307
 
I share your frustration Filo. But it’s my impression the safety data was manipulated by FGEN’s former management.
What I wonder about is whether the FDA will also look at MACE data from real world use of roxadustat in China & Japan, where I assume there haven’t been any major safety concerns.
Peace & good health,
Bulba


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News